CA2620425A1 - Derives d'anilinopyrazole utilises dans le traitement du diabete - Google Patents

Derives d'anilinopyrazole utilises dans le traitement du diabete Download PDF

Info

Publication number
CA2620425A1
CA2620425A1 CA002620425A CA2620425A CA2620425A1 CA 2620425 A1 CA2620425 A1 CA 2620425A1 CA 002620425 A CA002620425 A CA 002620425A CA 2620425 A CA2620425 A CA 2620425A CA 2620425 A1 CA2620425 A1 CA 2620425A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkoxy
pyrazol
alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002620425A
Other languages
English (en)
Inventor
Derek Lowe
Tatiana Shelekhin
Gan Wang
Xin Ma
Christiana Iwuagwu
Shihong Ying
Steven Magnuson
Joachim Rudolph
Johannes Koebberling
Josef Pernerstorfer
Thomas Mueller
Michael Brands
Dirk Heimbach
Niels Lindner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare Llc
Derek Lowe
Tatiana Shelekhin
Gan Wang
Xin Ma
Christiana Iwuagwu
Shihong Ying
Steven Magnuson
Joachim Rudolph
Johannes Koebberling
Josef Pernerstorfer
Thomas Mueller
Michael Brands
Dirk Heimbach
Niels Lindner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc, Derek Lowe, Tatiana Shelekhin, Gan Wang, Xin Ma, Christiana Iwuagwu, Shihong Ying, Steven Magnuson, Joachim Rudolph, Johannes Koebberling, Josef Pernerstorfer, Thomas Mueller, Michael Brands, Dirk Heimbach, Niels Lindner filed Critical Bayer Healthcare Llc
Publication of CA2620425A1 publication Critical patent/CA2620425A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002620425A 2005-08-31 2006-08-31 Derives d'anilinopyrazole utilises dans le traitement du diabete Abandoned CA2620425A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71314605P 2005-08-31 2005-08-31
US60/713,146 2005-08-31
PCT/US2006/033957 WO2007027842A1 (fr) 2005-08-31 2006-08-31 Derives d'anilinopyrazole utilises dans le traitement du diabete

Publications (1)

Publication Number Publication Date
CA2620425A1 true CA2620425A1 (fr) 2007-03-08

Family

ID=37607359

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002620425A Abandoned CA2620425A1 (fr) 2005-08-31 2006-08-31 Derives d'anilinopyrazole utilises dans le traitement du diabete

Country Status (4)

Country Link
EP (1) EP1928455A1 (fr)
JP (1) JP2009506127A (fr)
CA (1) CA2620425A1 (fr)
WO (1) WO2007027842A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113984726A (zh) * 2021-10-20 2022-01-28 上海大学 一种氨基苯硼酸功能化磁珠/乙二醛修饰dna检测汞离子的方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719797A8 (pt) * 2006-10-02 2017-12-26 Novartis Ag Compostos e composições como inibidores de proteína cinase
US8143424B2 (en) 2007-06-06 2012-03-27 Torrent Pharmaceuticals Ltd. Thyroid like compounds
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
EP2430013B1 (fr) * 2009-05-13 2014-10-15 Amgen Inc. Composés heteraryles comme inhibiteurs de la pikk
EP2266973A1 (fr) 2009-05-29 2010-12-29 Bayer CropScience AG Pyrazinylpyrazole
TW201116515A (en) 2009-07-31 2011-05-16 Organon Nv Dihydrobenzoindazoles
JP2013510815A (ja) 2009-11-11 2013-03-28 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 新規なジアジニルピラゾリル化合物
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
DE102010063691A1 (de) 2010-12-21 2012-06-21 Bayer Animal Health Gmbh Ektoparasitizide Wirkstoffkombinationen
WO2013046041A1 (fr) * 2011-09-30 2013-04-04 Synovo Gmbh Pyridinylpyrazoles destinés à être utilisés comme modulateurs de kinase dans le traitement du cancer
TWI568721B (zh) 2012-02-01 2017-02-01 杜邦股份有限公司 殺真菌之吡唑混合物
JP2016503395A (ja) 2012-10-31 2016-02-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 病害生物防除剤としての複素環化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134200C (fr) * 1960-04-14
JP2001342188A (ja) * 2000-03-27 2001-12-11 Takeda Chem Ind Ltd 縮合ピラゾール誘導体、その製造法および用途
CA2404669A1 (fr) * 2000-03-27 2001-10-04 Akiko Asakawa Derives de pyrazole condense, procede de production et utilisation
AR042067A1 (es) * 2002-11-27 2005-06-08 Bayer Pharmaceuticals Corp Derivados de anilinopirazol utiles en el tratamiento de la diabetes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113984726A (zh) * 2021-10-20 2022-01-28 上海大学 一种氨基苯硼酸功能化磁珠/乙二醛修饰dna检测汞离子的方法
CN113984726B (zh) * 2021-10-20 2024-02-02 上海大学 一种氨基苯硼酸功能化磁珠/乙二醛修饰dna检测汞离子的方法

Also Published As

Publication number Publication date
JP2009506127A (ja) 2009-02-12
EP1928455A1 (fr) 2008-06-11
WO2007027842A1 (fr) 2007-03-08

Similar Documents

Publication Publication Date Title
CA2620425A1 (fr) Derives d'anilinopyrazole utilises dans le traitement du diabete
JP6962941B2 (ja) Ａｐｊ受容体アゴニストとしての４−ヒドロキシ−３−スルホニルピリジン−２（１ｈ）−オン
AU2009245715B2 (en) Trisubstituted pyrazoles as acetylcholine receptor modulators
US7371767B2 (en) Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
US7517878B2 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
JP5312466B2 (ja) ８位置換イソキノリン誘導体及びその用途
US20080064734A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
JP3256513B2 (ja) ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
KR101342184B1 (ko) 사치환된 피리다진 헷지호그 경로 길항제
EP1996196A2 (fr) Agonistes de somatostatine
EP3704106A1 (fr) Composés d'alcène utilisés en tant que modulateurs du récepteur farnésoïde x
CA2567352A1 (fr) Derives de 5-anilino-4-heteroarylpyrazole utiles pour le traitement du diabete
EP4225753A1 (fr) Composés puissants et sélectifs utilisés en tant que modulateurs du récepteur de la sérotonine 1b
ZA200505055B (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA06008833A (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140703